Multiple sclerosis treatments generally manage the disease, instead of preventing the disease. A new vaccine in clinical trials provides promising results for the future.
According to Medical Xpress, “Scientists from the Institute of Bioorganic Chemistry of the Russian Academy of Sciences proposed a vaccine whose main component are liposomes (lipid vesicle conveyers). They contain fragments of myelin protein, which insulates nerve fibers in the body. In the experiment, three protein fragments were selected, one of which has a therapeutic effect in the early stages of the disease. The other two are used to prevent the development of pathologies during the remission stage. In the laboratory, it was found that the most effective option is the co-administration of all three fragments inside mannosylated liposomes.”
Preclinical tests were tested on rats and results established the positive effect of the myelin protein fragments.
“The vaccines developed were tested in a series of clinical trials on healthy volunteers and patients suffering from multiple sclerosis. These trials were conducted at five national centers in Russia. We discovered that the drug is well tolerated, and has a very low probability of developing adverse events,” says Alexey Belogurov.
This study is a starting point in the development of an effective treatment for multiple sclerosis.
Are you hopeful?
Image found at www.emedicinehealth.com.